Anika Therapeutics, Inc. (ANIK) Reports Q3 EPS of 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.49 +0.24%
Revenue Growth %: +5.9%
Financial Fact:
Research & development: 2.82M
Today's EPS Names:
OMID, BCML, CZNC, More
Revenue Growth %: +5.9%
Financial Fact:
Research & development: 2.82M
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q3 EPS of $0.22, vs. the analyst estimate of $0.11. Revenue for the quarter came in at $18.5 million versus the consensus estimate of $15.1 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
- UniFirst Corp (UNF) Misses Q4 EPS by 44c
- Teledyne Technologies (TDY) Tops Q3 EPS by 56c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
